Atomoxetine for suppression of vasovagal syncope

[1]  C. Morillo,et al.  Midodrine for the Prevention of Vasovagal Syncope , 2021, Annals of Internal Medicine.

[2]  S. Raj,et al.  Likelihood of injury due to vasovagal syncope: a systematic review and meta-analysis. , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[3]  S. Raj,et al.  Pharmacological norepinephrine transporter inhibition for the prevention of vasovagal syncope in young and adult subjects: A systematic review and meta-analysis. , 2020, Heart rhythm.

[4]  S. Raj,et al.  A proof of principle study of atomoxetine for the prevention of vasovagal syncope: the Prevention of Syncope Trial VI. , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  S. Raj,et al.  MIDODRINE FOR THE PREVENTION OF VASOVAGAL SYNCOPE: A SYSTEMATIC REVIEW AND META-ANALYSIS , 2019, Canadian Journal of Cardiology.

[6]  B. Grubb,et al.  The benefit of closed loop stimulation in patients with cardioinhibitory vasovagal syncope confirmed by head-up tilt table testing: a systematic review and meta-analysis , 2019, Journal of Interventional Cardiac Electrophysiology.

[7]  S. Raj,et al.  Reduced quality of life and greater psychological distress in vasovagal syncope patients compared to healthy individuals , 2018, Pacing and clinical electrophysiology : PACE.

[8]  J. Deharo,et al.  [2018 ESC Guidelines for the diagnosis and management of syncope]. , 2018, Kardiologia polska.

[9]  Christophe Leclercq,et al.  2018 ESC Guidelines for the diagnosis and management of syncope , 2018, European heart journal.

[10]  R. Sheldon,et al.  Clusters, Gaps, and Randomness: Vasovagal Syncope Recurrence Patterns. , 2017, JACC. Clinical electrophysiology.

[11]  M. Link,et al.  2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.

[12]  M. Link,et al.  2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Circulation.

[13]  R. Sheldon,et al.  High Remission Rates in Vasovagal Syncope: Systematic Review and Meta-Analysis of Observational and Randomized Studies. , 2017, JACC. Clinical electrophysiology.

[14]  C. Morillo,et al.  Fludrocortisone for the Prevention of Vasovagal Syncope: A Randomized, Placebo-Controlled Trial. , 2016, Journal of the American College of Cardiology.

[15]  C. Alatorre,et al.  Real‐World Dosing Patterns of Atomoxetine in Adults with Attention‐Deficit/Hyperactivity Disorder , 2015, CNS neuroscience & therapeutics.

[16]  S. Raj,et al.  Norepinephrine Transport Inhibition for Treatment of Vasovagal Syncope , 2013, Journal of cardiovascular electrophysiology.

[17]  S. Connolly,et al.  Diagnostic criteria for vasovagal syncope based on a quantitative history. , 2006, European heart journal.

[18]  A. S. Narasimha Murthy,et al.  An application of the Poisson distribution , 1946 .

[19]  E. Schömig,et al.  The extent of neuronal re-uptake of 3H-noradrenaline in isolated vasa deferentia and atria of the rat , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[20]  Blaschke.  Das Gesetz der kleinen Zahlen , 1898 .

[21]  OUP accepted manuscript , 2021, Europace.